Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
CytoGenix Announces Notice of Allowance in the U.S. for Herpes Patent
January 25th, 2008
CytoGenix, Inc. (OTCBB:CYGX) announced it has received a Notice of Allowance for a patent on its Herpes composition from the United States Patent and Trademark Office. The allowed patent entitled, "Treatment of HSV-Related Pathologies Using ssDNA," claims both the composition of matter utilizing the Company's single stranded DNA (ssDNA) expression vector technology and methods of treatment utilizing the therapeutic compound. While most pharmacological agents are employed to chemically signal cells to interrupt, reduce production or bind and regulate specific disease-causing proteins, this application of Cytogenix's novel ssDNA technology directs infected cell(s) to make...
Source: Medical Patent Business Week (2008-01-25)
|
